Visceral leishmaniasis: immunology and prospects for a vaccine.

Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.

• Publication year

  2011

• Venue

  Clinical Microbiology and Infection

• Publication date

  2011-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1469-0691.2011.03610.xPMID 21851483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

  2011cited by this paper
• Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.

  2011influential reference
• The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.

  2011influential reference
• Vaccines for the Leishmaniases: Proposals for a Research Agenda

  2011cited by this paper
• Canine visceral leishmaniasis in Teresina, Brazil: Relationship between clinical features and infectivity for sand flies.

  2011cited by this paper
• Multiple levels of gene regulation mediate differentiation of the intracellular pathogen Leishmania

  2011cited by this paper
• Dynamic Imaging of Experimental Leishmania donovani-Induced Hepatic Granulomas Detects Kupffer Cell-Restricted Antigen Presentation to Antigen-Specific CD8+ T Cells

  2010cited by this paper
• Immunomodulators: use in combined therapy against leishmaniasis

  2010cited by this paper
• Innate Killing of Leishmania donovani by Macrophages of the Splenic Marginal Zone Requires IRF-7

  2010cited by this paper
• Adaptive Immunity against Leishmania Nucleoside Hydrolase Maps Its C-Terminal Domain as the Target of the CD4+ T Cell–Driven Protective Response

  2010cited by this paper
• Immunological Perspectives of Leishmaniasis

  2010cited by this paper
• IgG1 Is Pathogenic in Leishmania mexicana Infection

  2010cited by this paper
• Leukocytes Infiltrate the Skin and Draining Lymph Nodes in Response to the Protozoan Leishmania infantum chagasi

  2010cited by this paper
• Prime-boost vectored malaria vaccines: Progress and prospects

  2010cited by this paper
• The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India

  2010cited by this paper
• Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.

  2010cited by this paper
• Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent

  2010cited by this paper
• Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine.

  2010cited by this paper
• A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.

  2010cited by this paper
• Leishmaniasis Vaccine: Where are We Today?

  2010cited by this paper
• Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis.

  2010cited by this paper
• Gel free analysis of the proteome of intracellular Leishmania mexicana.

  2010cited by this paper
• Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

  2010cited by this paper
• Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.

  2010cited by this paper
• Epidemiology of Leishmania donovani infection in high‐transmission foci in Nepal

  2010cited by this paper
• Murine visceral leishmaniasis: IgM and polyclonal B‐cell activation lead to disease exacerbation

  2010influential reference
• The epidemiology of Leishmania donovani infection in high transmission foci in India

  2010cited by this paper
• Immune evasive mechanisms contributing to persistent Leishmania donovani infection

  2010cited by this paper
• Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis.

  2010cited by this paper
• IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform

  2010cited by this paper
• Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.

  2009cited by this paper
• Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis.

  2009cited by this paper
• Cytokine profiles in canine visceral leishmaniasis.

  2009cited by this paper
• Current status and perspectives of the immunotherapy of leishmaniasis.

  2009cited by this paper
• Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era.

  2009cited by this paper
• A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis

  2009cited by this paper
• Immunobiology of leishmaniasis.

  2009cited by this paper
• Vaccines and vaccination strategies against human cutaneous leishmaniasis

  2009cited by this paper
• ISCOMs and ISCOMATRIX.

  2009cited by this paper
• Vector Transmission of Leishmania Abrogates Vaccine-Induced Protective Immunity

  2009cited by this paper
• Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.

  2009cited by this paper
• T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune.

  2009cited by this paper
• Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® + MPL-SE® vaccine to treat canine visceral leishmaniasis

  2008cited by this paper
• Codon usage suggests that translational selection has a major impact on protein expression in trypanosomatids

  2008cited by this paper
• Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis.

  2008cited by this paper
• Complexities of Assessing the Disease Burden Attributable to Leishmaniasis

  2008cited by this paper
• Transgenic, Fluorescent Leishmania mexicana Allow Direct Analysis of the Proteome of Intracellular Amastigotes*S

  2008cited by this paper
• Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research

  2008cited by this paper
• FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine

  2008cited by this paper
• Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.

  2008cited by this paper
• Interleukin-10 and the pathogenesis of human visceral leishmaniasis.

  2007cited by this paper
• Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy

  2007cited by this paper
• Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8+ Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but Not IL-4 or IL-13

  2007cited by this paper
• Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis

  2007influential reference
• Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed.

  2007cited by this paper
• Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

  2007cited by this paper
• Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework

  2007cited by this paper
• Infectivity of seropositive dogs, showing different clinical forms of leishmaniasis, to Lutzomyia longipalpis phlebotomine sand flies.

  2007cited by this paper
• Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

  2007cited by this paper
• Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis

  2007cited by this paper
• Bioinformatic Identification of Tandem Repeat Antigens of the Leishmania donovani Complex

  2006cited by this paper
• MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.

  2006cited by this paper
• Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine.

  2006cited by this paper
• Distinct roles for IL‐6 and IL‐12p40 in mediating protection against Leishmania donovani and the expansion of IL‐10+ CD4+ T cells

  2006cited by this paper
• Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana.

  2006cited by this paper
• In Vivo Recognition of Ovalbumin Expressed by Transgenic Leishmania Is Determined by Its Subcellular Localization1

  2006cited by this paper
• Cloning, Characterization, and Serodiagnostic Evaluation of Leishmania infantum Tandem Repeat Proteins

  2006cited by this paper
• Immunotherapy for drug-refractory mucosal leishmaniasis.

  2006cited by this paper
• Adoptive Immunotherapy against Experimental Visceral Leishmaniasis with CD8+ T Cells Requires the Presence of Cognate Antigen

  2006cited by this paper
• The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.

  2006cited by this paper
• From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection.

  2006cited by this paper
• Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.

  2006cited by this paper
• Advances in leishmaniasis.

  2005cited by this paper
• Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis.

  2005cited by this paper
• Consortium IGVThe Indian Genome Variation database (IGVdb): a project overview. Hum Genet 118:1-11

  2005cited by this paper
• Second-generation vaccines against leishmaniasis.

  2005cited by this paper
• Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.

  2005cited by this paper
• The Indian Genome Variation database (IGVdb): a project overview

  2005cited by this paper
• The Genome of the Kinetoplastid Parasite, Leishmania major

  2005cited by this paper
• Canine leishmaniasis.

  2004cited by this paper
• DNA-Salmonella enterica Serovar Typhimurium Primer-Booster Vaccination Biases towards T Helper 1 Responses and Enhances Protection against Leishmania major Infection in Mice

  2004cited by this paper
• The immunopathology of experimental visceral leishmaniasis

  2004cited by this paper
• From genomes to vaccines for leishmaniasis.

  2004cited by this paper
• Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations

  2003cited by this paper
• Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach.

  2003cited by this paper
• Post-kala-azar dermal leishmaniasis.

  2003cited by this paper
• Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses

  2003cited by this paper
• Both Interleukin-4 (IL-4) and IL-4 Receptor α Signaling Contribute to the Development of Hepatic Granulomas with Optimal Antileishmanial Activity

  2003cited by this paper
• Can needle-free administration of vaccines become the norm in global immunization?

  2003cited by this paper
• Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine

  2003cited by this paper
• Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods

  2003cited by this paper
• Reliable prediction of T-cell epitopes using neural networks with novel sequence representations

  2002cited by this paper
• Vaccination with Plasmid DNA Encoding TSA/LmSTI1 Leishmanial Fusion Proteins Confers Protection against Leishmania major Infection in Susceptible BALB/c Mice

  2002cited by this paper
• Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission.

  2002cited by this paper
• From genomes to vaccines: Leishmania as a model.

  2002cited by this paper
• Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).

  2002cited by this paper
• Leishmaniasis in Sudan. 3. Visceral leishmaniasis

  2001cited by this paper
• The Potency and Durability of DNA- and Protein-Based Vaccines Against Leishmania major Evaluated Using Low-Dose, Intradermal Challenge

  2001cited by this paper
• Leishmaniasis in Sudan. Visceral leishmaniasis.

  2001cited by this paper
• Identification and Characterization of T Cell-Stimulating Antigens from Leishmania by CD4 T Cell Expression Cloning1

  2001cited by this paper

• Efficacy and safety of different drugs for the treatment of leishmaniasis: a systematic review and network meta-analysis

  2025cites this paper
• Co-infection with Pseudomonas aeruginosa and Leishmania donovani affects the antiparasitic immunity of RAW264.7 macrophages via the NOD-like receptor pathway in vitro.

  2025cites this paper
• Diagnostic potential of GLP recombinant antigens in whole blood assays for Leishmania infantum infection

  2025cites this paper
• Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis

  2025cites this paper
• New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine

  2024cites this paper
• Immunotherapy and immunochemotherapy in combating visceral leishmaniasis

  2023cites this paper
• Elucidation of conserved multi-epitope vaccine against Leishmania donovani using reverse vaccinology

  2023cites this paper
• Host SUMOylation Pathway Negatively Regulates Protective Immune Responses and Promotes Leishmania donovani Survival

  2022cites this paper
• Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis

  2022cites this paper
• Visceral Leishmaniasis and the Skin: Dermal Parasite Transmission to Sand Flies

  2022cites this paper
• Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis

  2022cites this paper
• Chronic Systemic Infection of Mice with Leishmania infantum Leads to Increased Bone Mass

  2022cites this paper
• From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection

  2021cites this paper
• Immune response dynamics and Lutzomyia longipalpis exposure characterize a biosignature of visceral leishmaniasis susceptibility in a canine cohort

  2021cites this paper
• Designing of a Novel Fusion Protein Vaccine Candidate Against Human Visceral Leishmaniasis (VL) Using Immunoinformatics and Structural Approaches

  2021cites this paper
• Vaccine as immunotherapy for leishmaniasis

  2021cites this paper
• Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis

  2021cites this paper
• Evaluation of transgenic Leishmania infantum expressing mLLO‐BAX‐SMAC in the apoptosis of the infected macrophages in vitro and in vivo

  2020cites this paper
• Susceptibility to Intracellular Infections: Contributions of TNF to Immune Defense

  2020cites this paper
• Resistance to Experimental Visceral Leishmaniasis in Mice Infected With Leishmania infantum Requires Batf3

  2020cites this paper
• Whole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation

  2020cites this paper
• Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis.

  2020cites this paper
• An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes

  2019cites this paper
• Neutrophil elastase promotes Leishmania donovani infection via interferon-β

  2019cites this paper
• Novos adjuvantes vacinais: importante ferramenta para imunoterapia da leishmaniose visceral

  2019cites this paper
• Vaccination with a CD4+ and CD8+ T‐cell epitopes‐based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis

  2018cites this paper
• Vaccines for Human Leishmaniasis: Where Do We Stand and What Is Still Missing?

  2018cites this paper
• Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice

  2018cites this paper
• Recent progress in drug targets and inhibitors towards combating leishmaniasis.

  2018cites this paper
• Peptide Vaccines for Leishmaniasis

  2018influential citation
• Infection of Human Monocytes with Leishmania infantum Strains Induces a Downmodulated Response when Compared with Infection with Leishmania braziliensis

  2018cites this paper
• Live Attenuated Leishmania donovani Centrin Gene–Deleted Parasites Induce IL-23–Dependent IL-17–Protective Immune Response against Visceral Leishmaniasis in a Murine Model

  2018cites this paper
• Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control

  2018cites this paper
• A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection

  2017cites this paper
• Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis

  2017cites this paper
• Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach

  2017cites this paper
• Probing the efficacy of a heterologous Leishmania/L. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice.

  2017cites this paper
• F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis

  2017cites this paper
• Zinc Enzyme Inhibitors: Enzymes from Microorganisms

  2017cites this paper
• Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis

  2017cites this paper
• Novel Areas for Prevention and Control of Canine Leishmaniosis.

  2017cites this paper
• Leishmania infantum-specific IFN-γ production in stimulated blood from dogs with clinical leishmaniosis at diagnosis and during treatment.

  2017cites this paper
• The Eukaryotic Elongation Factor 1 Alpha (eEF1α) from the Parasite Leishmania infantum Is Modified with the Immunomodulatory Substituent Phosphorylcholine (PC)

  2017cites this paper
• A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

  2017cites this paper
• Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis

  2016cites this paper
• This information is current as Progressive Visceral Leishmaniasis Function via IL-10 and PD-L 1 during B Cells Suppress T CellhiRegulatory IgD

  2016cites this paper
• The leishmanicidal activity of oleuropein is selectively regulated through inflammation- and oxidative stress-related genes

  2016cites this paper
• Differential Role of Leptin as an Immunomodulator in Controlling Visceral Leishmaniasis in Normal and Leptin-Deficient Mice

  2016cites this paper
• Neutrophil responses to infection with Leishmania parasites: MHC class II-expression and parasite life-stage interactions

  2016cites this paper
• DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control

  2016cites this paper
• Protozoan Carbonic Anhydrases

  2016cites this paper
• Uniting mathematics and biology for control of visceral leishmaniasis.

  2015cites this paper
• Leishmanicidal Activity of Piper nigrum Bioactive Fractions is Interceded via Apoptosis In Vitro and Substantiated by Th1 Immunostimulatory Potential In Vivo

  2015cites this paper
• From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE

  2015cites this paper
• Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study

  2015cites this paper
• Epidemiologic, clinical, diagnostic and therapeutic aspects of visceral leishmaniasis in renal transplant recipients: experience from thirty cases

  2015cites this paper
• An overview on Leishmania vaccines: A narrative review article

  2015cites this paper
• Vaccines for visceral leishmaniasis: A review.

  2015cites this paper
• Leishmania donovani influenced cytokines and Toll‐like receptors expression among Sudanese visceral leishmaniasis patients

  2015cites this paper
• Timing is everything: dendritic cell subsets in murine Leishmania infection.

  2014cites this paper
• Formulation of Particulate-based Immunomodulatory Therapeutics for the Treatment of Diseases

  2014cites this paper
• Regulação da expressão do transportador de aminoácidos de Leishmania (Leishmania) amazonensis

  2014cites this paper
• Regulation of immunity to visceral Leishmania in a non-human primate model of infection

  2014cites this paper
• Arsenic, antimony and visceral leishmaniasis

  2014cites this paper
• Therapeutic vaccines for leishmaniasis

  2014cites this paper
• Visceral Leishmaniasis in Renal Transplant Recipients: Study of 30 Cases

  2014cites this paper
• Molecular mechanisms of in vitro betulin-induced apoptosis of Leishmania donovani.

  2014cites this paper
• Liposomal resiquimod for the treatment of Leishmania donovani infection.

  2014cites this paper
• Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins

  2014cites this paper
• Clinical and Parasitological Protection in a Leishmania infantum-Macaque Model Vaccinated with Adenovirus and the Recombinant A2 Antigen

  2014influential citation
• Modular Multiantigen T Cell Epitope–Enriched DNA Vaccine Against Human Leishmaniasis

  2014cites this paper
• Genetically Modified Organisms and Visceral Leishmaniasis

  2014cites this paper
• Immunoregulation in human American leishmaniasis: balancing pathology and protection

  2014cites this paper
• Programmed Death 1–Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Function

  2013cites this paper
• Evaluation of the protozoan parasite L. tarentolae as a eukaryotic expression host in biomedical research

  2013cites this paper
• "Duração da imunidade vacinal na Leishmaniose visceral canina: Perfil fenotípico e funcional da atividade fagocítica anti-Leishmania chagasi"

  2013cites this paper
• Mechanisms of immunity and pathology during canine leishmaniasis: Leading the way to prevention and treatment

  2013cites this paper
• Implication des Galectines-3, 7 et 9 dans la réponse immunitaire contre le parasite Leishmania major

  2013cites this paper
• This information is current as Impairs Phagocyte Function Exhaustion during Visceral Leishmaniasis Mediated T Cell − Programmed Death 1

  2013cites this paper
• Cysteine peptidase inhibitors in trypanosomatid parasites.

  2013cites this paper
• Seroprevalence and asymptomatic carriage of Leishmania spp. in Austria, a non-endemic European country.

  2013cites this paper
• "Eczema-like" leishmaniasis in an HIV patient.

  2013cites this paper
• Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: inhibition of key redox enzymes of the pathogen.

  2013cites this paper
• Anti-leishmanial activity of heteroleptic organometallic Sb(v) compounds.

  2013cites this paper
• A Petri Net Model of Granulomatous Inflammation: Implications for IL-10 Mediated Control of Leishmania donovani Infection

  2013cites this paper
• Do you see what I see: Recognition of protozoan parasites by Toll-like receptors.

  2013cites this paper
• Live Attenuated Leishmania donovani p27 Gene Knockout Parasites Are Nonpathogenic and Elicit Long-Term Protective Immunity in BALB/c Mice

  2013cites this paper
• Efficacy of biogenic selenium nanoparticles against Leishmania major: in vitro and in vivo studies.

  2013cites this paper
• Therapeutic Vaccination With Recombinant Adenovirus Reduces Splenic Parasite Burden in Experimental Visceral Leishmaniasis

  2012cites this paper
• Head-to-Head Comparison of Three Vaccination Strategies Based on DNA and Raw Insect-Derived Recombinant Proteins against Leishmania

  2012cites this paper
• Caracterização cinética e estrutural do sintase do óxido nítrico de Leishmania infantum

  2012cites this paper
• Deletion of mitochondrial associated ubiquitin fold modifier protein Ufm1 in Leishmania donovani results in loss of β‐oxidation of fatty acids and blocks cell division in the amastigote stage

  2012cites this paper
• Killed but Metabolically Active Leishmania infantum as a Novel Whole-Cell Vaccine for Visceral Leishmaniasis

  2012cites this paper
• Marchantin A, a macrocyclic bisbibenzyl ether, isolated from the liverwort Marchantia polymorpha, inhibits protozoal growth in vitro.

  2012cites this paper
• a Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance,

  2012cites this paper
• The Leishmania TDR1 family-related gene: functional studies and evaluation of TDR1 recombinant protein as a vaccine agaist leishmaniasis

  2012cites this paper
• Evaluation of Recombinant Leishmania Polyprotein Plus Glucopyranosyl Lipid A Stable Emulsion Vaccines against Sand Fly-Transmitted Leishmania major in C57BL/6 Mice

  2012cites this paper
• Toll-Like Receptors in Leishmania Infections: Guardians or Promoters?

  2012cites this paper
• Characterization of Leishmania infantum thiol‐dependent reductase 1 and evaluation of its potential to induce immune protection

  2012cites this paper
• Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.

  2012cites this paper